Free Trial
NYSEAMERICAN:HEB

Hemispherx BioPharma (HEB) Stock Price, News & Analysis

Hemispherx BioPharma logo

About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.09
$0.22
52-Week Range
N/A
Volume
2.31 million shs
Average Volume
102,599 shs
Market Capitalization
$232,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Receive HEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HEB Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
H-E-B hosting hiring fairs
See More Headlines

HEB Stock Analysis - Frequently Asked Questions

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, beating analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter.

Shares of Hemispherx BioPharma reverse split before market open on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN) and Ayala Pharmaceuticals (ADXS).

Company Calendar

Last Earnings
8/15/2019
Today
5/04/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:HEB
Previous Symbol
NYSE:HEB
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$232,000.00
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NYSEAMERICAN:HEB) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners